At the 2026 American College of Cardiology (ACC) Scientific Session in New Orleans, researchers presented a meta-analysis of randomized trials assessing baxdrostat in patients with uncontrolled hypertension on standard therapy. The analysis combined three randomized controlled trials including 1,264 patients and evaluated blood pressure outcomes and safety.
Uncontrolled hypertension continues to drive cardiovascular events and organ damage despite broad use of multiple antihypertensive classes. Patients who remain above target blood pressure on standard combinations often require further treatment intensification, but current late-line options can be limited by tolerability, monitoring needs, and access.
Go deeper with GlobalData
The investigators conducted a systematic search across three databases up to September 2025 and included trials that randomized patients with uncontrolled hypertension to baxdrostat or control on top of background therapy. Baxdrostat is a selective aldosterone synthase inhibitor designed to reduce aldosterone production and downstream sodium retention while avoiding some of the off-target effects seen with mineralocorticoid receptor antagonists.
Across the three trials, baxdrostat reduced systolic blood pressure by 9.17 mm Hg compared with control, with narrow confidence intervals and no observed heterogeneity between studies. Diastolic blood pressure fell by 3.56 mm Hg, again with consistent results across the dataset. Certainty of evidence was rated as moderate to high, which supports use of these findings in future guideline and policy discussions.
On safety, baxdrostat was associated with a modest increase in overall adverse events but no significant differences in serious adverse events or hypotension. Subgroup analysis indicated that lower doses in the 0.5–1 mg range provided the most favorable balance between efficacy and safety, suggesting that optimized dosing will be important if baxdrostat moves into broader clinical use.
Experts are likely to see this meta-analysis as confirmation that aldosterone synthase inhibition can deliver additional blood pressure reduction in patients who are not controlled on standard regimens. KOLs will likely focus on how baxdrostat compares with mineralocorticoid receptor antagonists in routine practice and which patient subgroups, such as those with chronic kidney disease or high cardiovascular risk, may benefit most.
From a strategic perspective, these results support baxdrostat as a potential late-line add-on for uncontrolled hypertension rather than a competitor to low-cost first-line agents. The data strengthen the case for continued development, but meaningful commercial impact will depend on demonstrating advantages over existing generic options, clear treatment algorithms for resistant disease, and practical safety monitoring that fits into primary care workflows.
Looking ahead, further phase III and long-term studies will be needed to show whether baxdrostat-driven blood pressure reductions translate into fewer cardiovascular events and hospitalizations. If upcoming data confirm durable benefit with an acceptable safety profile, baxdrostat could become an important option in resistant hypertension pathways and increase interest in aldosterone synthase inhibition across the cardiovascular pipeline
